For the quarter ending 2025-09-30, ABEO made $7,917K in revenue. -$5,106K in net income. Net profit margin of -64.49%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Cost of sales | 488 | - | - | - |
| General and administrative | - | - | 9,786 | 6,404 |
| Research and development | 4,216 | 5,943 | 9,941 | 8,941 |
| License and other revenues | - | 400 | - | - |
| Royalties | - | 100 | - | - |
| Selling, general and administrative | 19,314 | 17,149 | - | - |
| Total expenses | - | 23,192 | 19,727 | 15,345 |
| Total costs and expenses | 24,018 | - | - | - |
| Loss from operations | -24,018 | -22,792 | -19,727 | -15,345 |
| Interest income | 1,672 | 1,027 | 1,310 | 1,189 |
| Interest expense | 901 | 957 | 998 | 1,102 |
| Change in fair value of warrant and derivative liabilities | -2,760 | 5,388 | -7,245 | 15,156 |
| Gain from sale of priority review voucher, net | - | 152,366 | - | - |
| Other income | 129 | 89 | 141 | 145 |
| Income (loss) before income taxes | -20,358 | 124,345 | - | - |
| Income tax (benefit) expense | -15,197 | 15,512 | - | - |
| Net (loss) income | -5,161 | 108,833 | -12,029 | -30,269 |
| Change in unrealized gains related to available-for-sale debt securities | 55 | 22 | -75 | 50 |
| Comprehensive (loss) income | -5,106 | 108,855 | -12,104 | -30,219 |
| Basic | 54,242,507 | 52,524,510 | 49,778,801 | 48,081,758 |
| Basic (loss) income per common share | -0.1 | 2.07 | -0.24 | -0.63 |
| Dilutive | 54,242,507 | 66,640,620 | 49,778,801 | 48,081,758 |
| Dilutive (loss) income per common share | -0.1 | 1.71 | -0.24 | -0.63 |
ABEONA THERAPEUTICS INC. (ABEO)
ABEONA THERAPEUTICS INC. (ABEO)